Neoadjuvant therapy in pancreatic cancer: An emerging strategy

Gastroenterology Research and Practice

Volumn 2014, Issue , 2014, Pages

  Bittoni, Alessandro ^a   Santoni, Matteo ^a   Lanese, Andrea ^a   Pellei, Chiara ^a   Andrikou, Kalliopi ^a   Stefano, Cascinu ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; CETUXIMAB; CISPLATIN; CP 870893; EPIRUBICIN; ERLOTINIB; FLUOROURACIL; GEMCITABINE; HYDROXYCHLOROQUINE; IRINOTECAN; NELFINAVIR; OXALIPLATIN; PACLITAXEL; SONIDEGIB; TEGAFUR;

ADVANCED CANCER; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; DRUG EFFICACY; HUMAN; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; REVIEW;

EID: 84904688789     PISSN: 16876121     EISSN: 1687630X     Source Type: Journal    
DOI: 10.1155/2014/183852     Document Type: Review

References (38)

1. Hidalgo M., Pancreatic cancer. The New England Journal of Medicine 2010 362 17 1605 1617 10.1056/NEJMra0901557 2-s2.0-77951755278
2. Ueno H., Kosuge T., Matsuyama Y., Yamamoto J., Nakao A., Egawa S., Doi R., Monden M., Hatori T., Tanaka M., Shimada M., Kanemitsu K., A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer. British Journal of Cancer 2009 101 6 908 915 10.1038/sj.bjc.6605256 2-s2.0-70249099504
3. Oettle H., Post S., Neuhaus P., Gellert K., Langrehr J., Ridwelski K., Schramm H., Fahlke J., Zuelke C., Burkart C., Gutberlet K., Kettner E., Schmalenberg H., Weigang-Koehler K., Bechstein W., Niedergethmann M., Schmidt-Wolf I., Roll L., Doerken B., Riess H., Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. Journal of the American Medical Association 2007 297 3 267 277 10.1001/jama.297.3.267 2-s2.0-33846405332 (Pubitemid 46143304)
4. Chang D. K., Johns A. L., Merrett N. D., Margin clearence and outcome in resected pancreatic cancer. Journal of Clinical Oncology 2009 27 17 2855 2862 10.1200/JCO.2008.20.5104
5. Sukharamwala P., Thoens J., Szuchmacher M., Advanced age is a risk factor for post-operative complications and mortality after a pancreaticoduodenectomy: a meta-analysis and systematic review. HPB 2012 14 10 649 657
6. Neoptolemos J. P., Stocken D. D., Friess H., Bassi C., Dunn J. A., Hickey H., Beger H., Fernandez-Cruz L., Dervenis C., Lacaine F., Falconi M., Pederzoli P., Pap A., Spooner D., Kerr D. J., Büchler M. W., A Randomized Trial of Chemoradiotherapy and Chemotherapy after Resection of Pancreatic Cancer. The New England Journal of Medicine 2004 350 12 1200 1210 10.1056/NEJMoa032295 2-s2.0-12144287320 (Pubitemid 38339364)
7. Kalser M. H., Ellenberg S. S., Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Archives of Surgery 1985 120 8 899 903 10.1001/archsurg.1985.01390320023003 2-s2.0-0021867923 (Pubitemid 15040883)
8. Klinkenbijl J. H., Jeekel J., Sahmoud T., Van Pel R., Couvreur M. L., Veenhof C. H., Arnaud J. P., Gonzalez D. G., De Wit L. T., Hennipman A., Wils J., Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC Gastrointestinal Tract Cancer Cooperative Group. Annals of Surgery 1999 230 6 776 784 10.1097/00000658-199912000-00006 2-s2.0-0033497862 (Pubitemid 30191812)
9. Palmer D. H., Stocken D. D., Hewitt H., Markham C. E., Hassan A. B., Johnson P. J., Buckels J. A. C., Bramhall S. R., A randomized phase 2 trial of neoadjuvant chemotherapy in resectable pancreatic cancer: gemcitabine alone versus gemcitabine combined with cisplatin. Annals of Surgical Oncology 2007 14 7 2088 2096 10.1245/s10434-007-9384-x 2-s2.0-34250816847 (Pubitemid 46988260)
10. Heinrich S., Pestalozzi B. C., Schäfer M., Weber A., Bauerfeind P., Knuth A., Clavien P., Prospective phase II trial of neoadjuvant chemotherapy with gemcitabine and cisplatin for resectable adenocarcinoma of the pancreatic head. Journal of Clinical Oncology 2008 26 15 2526 2531 10.1200/JCO.2007.15.5556 2-s2.0-45149091560
11. Evans D. B., Rich T. A., Byrd D. R., Cleary K. R., Connelly J. H., Levin B., Charnsangavej C., Fenoglio C. J., Ames F. C., Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Archives of Surgery 1992 127 11 1335 1339 10.1001/archsurg.1992.01420110083017 2-s2.0-0026454511
12. Evans D. B., Varadhachary G. R., Crane C. H., Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. Journal of Clinical Oncology 2008 26 21 3496 3502 10.1200/JCO.2007.15.8634
13. Varadhachary G. R., Wolff R. A., Crane C. H., Sun C. C., Lee J. E., Pisters P. W. T., Vauthey J., Abdalla E., Wang H., Staerkel G. A., Lee J. H., Ross W. A., Tamm E. P., Bhosale P. R., Krishnan S., Das P., Ho L., Xiong H., Abbruzzese J. L., Evans D. B., Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. Journal of Clinical Oncology 2008 26 21 3487 3495 10.1200/JCO.2007.15.8642 2-s2.0-49049102131
14. Pisters P. W. T., Wolff R. A., Janjan N. A., Cleary K. R., Charnsangavej C., Crane C. N., Lenzi R., Vauthey J. N., Lee J. E., Abbruzzese J. L., Evans D. B., Preoperative paclitaxel and concurrent rapid-fractionation radiation for resectable pancreatic adenocarcinoma: Toxicities, histologic response rates, and event-free outcome. Journal of Clinical Oncology 2002 20 10 2537 2544 10.1200/JCO.2002.11.064 2-s2.0-0037092960 (Pubitemid 34525741)
15. Mizuma M., Motoi F., Ishida K., Neoadjuvant chemotherapy with gemcitabine and S-1 for resectable and borderline pancreatic ductal adenocarcinoma: a prospective, multi-institutional, phase II trial. Journal of Clinical Oncology 2014 32, abstract 283 supplement 3
16. Hosein P. J., Macintyre J., Kawamura C., Maldonado J. C., Ernani V., Loaiza-Bonilla A., Narayanan G., Ribeiro A., Portelance L., Merchan J. R., Levi J. U., Rocha-Lima C. M., A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma. BMC Cancer 2012 12, article 199 10.1186/1471-2407-12-199 2-s2.0-84861465672
17. Gunturu K. S., Yao X., Cong X., Thumar J. R., Hochster H. S., Stein S. M., Lacy J., FOLFIRINOX for locally advanced and metastatic pancreatic cancer: single institution retrospective review of efficacy and toxicity. Medical Oncology 2013 30 1, article 361 10.1007/s12032-012-0361-2 2-s2.0-84880597386
18. Peddi P. F., Lubner S., McWilliams R., Tan B. R., Picus J., Sorscher S. M., Suresh R., Craig Lockhart A., Wang J., Menias C., Gao F., Linehan D., Wang-Gillam A., Multi-institutional experience with FOLFIRINOX in pancreatic adenocarcinoma. Journal of the Pancreas 2012 13 5 497 501 2-s2.0-84866378244
19. Blazer M. A., Wu C., Goldberg R., Tolerability and efficacy of modified FOLFIRINOX (mFOLFIRINOX) in patients with borderline-resectable pancreatic cancer (BRPC) and locally advanced unresectable pancreatic cancer (LAURPC). Journal of Clinical Oncology 2014 32, abstract 275 supplement 3
20. Vasile E., de Lio N., Cappelli C., Phase II study of neoadjuvant chemotherapy with modified FOLFOXIRI in borderline resectable or unresectable stage III pancreatic cancer. Journal of Clinical Oncology 2013 31, abstract 4062 supplement
21. Kunzmann V., Hartlapp I., Scheurlen M., Sequential neoadjuvant chemotherpy with nab-paclitaxel plus gemcitabine and FOLFIRINOX in locally advanced pancreatic cancer (LAPC): a PILOT study. Journal of Clinical Oncology 2013 31, abstract e15193 supplement
22. Katz M. H. G., Marsh R., Herman J. M., Shi Q., Collison E., Venook A. P., Kindler H. L., Alberts S. R., Philip P., Lowy A. M., Pisters P. W. T., Posner M. C., Berlin J. D., Ahmad S. A., Borderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial design. Annals of Surgical Oncology 2013 1 9 10.1245/s10434-013-2886-9 2-s2.0-84874008458
23. NCCN guidelines, Pancreatic adenocarcinoma. version 2, 2012
24. Katz M. H. G., Pisters P. W. T., Evans D. B., Sun C. C., Lee J. E., Fleming J. B., Vauthey J. N., Abdalla E. K., Crane C. H., Wolff R. A., Varadhachary G. R., Hwang R. F., Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. Journal of the American College of Surgeons 2008 206 5 833 846 10.1016/j.jamcollsurg.2007.12.020 2-s2.0-43049106807
25. Massucco P., Capussotti L., Magnino A., Sperti E., Gatti M., Muratore A., Sgotto E., Gabriele P., Aglietta M., Pancreatic resections after chemoradiotherapy for locally advanced ductal adenocarcinoma: analysis of perioperative outcome and survival. Annals of Surgical Oncology 2006 13 9 1201 1208 10.1245/s10434-006-9032-x 2-s2.0-33748962008 (Pubitemid 44440421)
26. Patel M., Hoffe S., Malafa M., Hodul P., Klapman J., Centeno B., Kim J., Helm J., Valone T., Springett G., Neoadjuvant GTX Chemotherapy and IMRT-based chemoradiation for borderline resectable pancreatic cancer. Journal of Surgical Oncology 2011 104 2 155 161 10.1002/jso.21954 2-s2.0-79959928329
27. Stokes J. B., Nolan N. J., Stelow E. B., Walters D. M., Weiss G. R., De Lange E. E., Rich T. A., Adams R. B., Bauer T. W., Preoperative capecitabine and concurrent radiation for borderline resectable pancreatic cancer. Annals of Surgical Oncology 2011 18 3 619 627 10.1245/s10434-010-1456-7 2-s2.0-79955739621
28. Kim E. J., Ben-Josef E., Herman J. M., Bekaii-Saab T., Dawson L. A., Griffith K. A., Francis I. R., Greenson J. K., Simeone D. M., Lawrence T. S., Laheru D., Wolfgang C. L., Williams T., Bloomston M., Moore M. J., Wei A., Zalupski M. M., A multi-institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer. Cancer 2013 119 15 2692 2700 10.1002/cncr.28117 2-s2.0-84880573171
29. Louvet C., Labianca R., Hammel P., Lledo G., Zampino M. G., André T., Zaniboni A., Ducreux M., Aitini E., Taïeb J., Faroux R., Lepere C., De Gramont A., Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. Journal of Clinical Oncology 2005 23 15 3509 3516 10.1200/JCO.2005.06.023 2-s2.0-20644464360
30. Lima C. M. R., Green M. R., Rotche R., Miller W. H. Jr., Jeffrey G. M., Cisar L. A., Morganti A., Orlando N., Gruia G., Miller L. L., Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. Journal of Clinical Oncology 2004 22 18 3776 3783 10.1200/JCO.2004.12.082 2-s2.0-4644327989 (Pubitemid 41095218)
31. Sahora K., Kuehrer I., Eisenhut A., Akan B., Koellblinger C., Goetzinger P., Teleky B., Jakesz R., Peck-Radosavljevic M., Ba'ssalamah A., Zielinski C., Gnant M., NeoGemOx: gemcitabine and oxaliplatin as neoadjuvant treatment for locally advanced, nonmetastasized pancreatic cancer. Surgery 2011 149 3 311 320 10.1016/j.surg.2010.07.048 2-s2.0-79951954901
32. Lee J. L., Kim S. C., Kim J. H., Lee S. S., Kim T. W., Park D. H., Seo D. W., Lee S. K., Kim M. H., Kim J. H., Park J. H., Shin S. H., Han D. J., Prospective efficacy and safety study of neoadjuvant gemcitabine with capecitabine combination chemotherapy for borderline-resectable or unresectable locally advanced pancreatic adenocarcinoma. Surgery 2012 152 5 851 862 10.1016/j.surg.2012.03.010 2-s2.0-84867580625
33. Reni M., Cereda S., Balzano G., Passoni P., Rognone A., Zerbi A., Nicoletti R., Mazza E., Arcidiacono P. G., Di Carlo V., Villa E., Outcome of upfront combination chemotherapy followed by chemoradiation for locally advanced pancreatic adenocarcinoma. Cancer Chemotherapy and Pharmacology 2009 64 6 1253 1259 10.1007/s00280-009-0995-8 2-s2.0-69049094889
34. Zhu C. P., Shi J., Chen Y. X., Xie W., Lin Y., Gemcitabine in the chemoradiotherapy for locally advanced pancreatic cancer: a meta-analysis. Radiotherapy and Oncology 2011 99 2 108 113 10.1016/j.radonc.2011.04.001 2-s2.0-79958172857
35. Gillen S., Schuster T., Büschenfelde C. M. Z., Friess H., Kleeff J., Preoperative/neoadjuvant therapy in pancreatic cancer: A systematic review and meta-analysis of response and resection percentages. PLoS Medicine 2010 7 4 e1000267 10.1371/journal.pmed.1000267 2-s2.0-77951709577
36. Conroy T., Desseigne F., Ychou M., FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. The New England Journal of Medicine 2011 364 19 1817 1825 10.1056/NEJMoa1011923
37. von Hoff D. D., Ervin T., Arena F. P., Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. New England Journal of Medicine 2013 369 18 1691 1703 10.1056/NEJMoa1304369
38. Barugola G., Partelli S., Marcucci S., Sartori N., Capelli P., Bassi C., Pederzoli P., Falconi M., Resectable pancreatic cancer: who really benefits from resection? Annals of Surgical Oncology 2009 16 12 3316 3322 10.1245/s10434-009-0670-7 2-s2.0-71549133022